CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

Read more

Our innovative solutions

CarThera’s medical devices allow for the treatment of brain tumors in outpatient procedures as well as for improvement in the bioavailability of chemotherapeutics

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

Read more

SonoCloud®

High Intensity Contact Ultrasound interstitial medical device

An implant that increases the intracerebral penetration of oncology drugs (+400%) by transiently opening the blood-brain barrier (BBB) without increasing dose or subsequent toxicity. The minimally invasive and easy to use SonoCloud® device is also applicable to the treatment of neurodegenerative diseases (e.g. Alzheimer’s).

Read more

 

SonoProbe®

High Intensity Contact Ultrasound interstitial medical device

img2

The only medical device capable of performing biopsy, treatment, and resection of brain tumors in a single, image-guided outpatient procedure, even for complex tumor geometries

The SonoProbe can also be used for the treatment of tumors located in other organs such as the liver or lung

Read more

Home Page
  • unnamed-2
    unnamed-3

     
  • News CarThera

    09.06.2020
    June 2020: CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

    CarThera announces that the first patient has been enrolled and treated in a clinical trial evaluating the safety of using its SonoCloud® technology in combination with checkpoint inhibitors for the treatment of brain metastases from melanoma (NCT04021420). In this trial, anti-PD1 alone or in combination with anti-CTLA4 are administered in patients before SonoCloud-mediated Blood Brain Barrier opening (BBB). BBB opening can help boost the brain’s immunity and increase brain penetration of newly approved systemically delivered immunotherapies, such as checkpoint inhibitors. This could translate into controlling brain disease with the same magnitude as peripheral diseases, improving clinical outcomes for many patients worldwide.

    09.06.2020
    December 2019: CarThera signs a strategic collaboration with Lantheus for its SonoCloud device microbubbles

    CarThera will partner with Lantheus for the supply of microbubbles. Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. Lantheus’ microbubbles will become an integrated component of the SonoCloud product. This agreement strengthens the configuration of the SonoCloud system and secures the supply of the microbubbles for the coming years.

    09.06.2020
    November 2019: CarThera and KIYATEC collaborate in effort to bring personalized medicine to patients stricken by brain cancer

    Under the terms of the clinical collaboration, KIYATEC will conduct ex vivo drug response profiling on glioblastoma tissue samples from patients enrolled in CarThera’s clinical study. CarThera will benefit from having ex vivo drug response profiling for patients enrolled in its study, while KIYATEC will correlate its patient-specific, pre-treatment drug response predictions with actual clinical outcomes of patients in CarThera’s study. For both companies, this collaboration represents an opportunity to enrich their portfolios of clinical evidence with the goal of helping clinicians improve outcomes for their patients with glioblastoma.